Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 3 Trial Investigating Blinatumomab ( NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B ALL) and the Treatment of Patients With Localized B Lymphoblastic Lymphoma (B LLy)
NCT Number:
NCT03914625
Phase:
III
Protocol Type:
Treatment
Age Group:
Both
Disease Sites:
Non-Hodgkin's Lymphoma
Study Objectives:
This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread.
Study Documents
(MUSC NetID required for document access)